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This is the ﬁrst issue of Metal Based Drugs, our journal,
restyled and resumed after 5 years’ silence. A number of dis-
tinguished scientists have agreed to be Associate Editors and
to assist in the new course of this multidisciplinary journal,
to encourage it to survive and to be the forum where to post
the most important ﬁndings of our intriguing research of
new and innovative metal-based drugs. With your help, the
journal has an excellentpotential to rapidly become the most
important reference in the biomedical literature of drugs for
diseases such as cancer and diabetes or for diagnostics based
onthemodernmolecularapproachformetalsinbiologyand
medicine.
Undoubtedly, of the many ﬁelds where metals can help
medicine with innovative drugs, chemotherapy and particu-
larly cancer chemotherapy is forever attracting considerable
interest. In this context it is important to note that there is
a decreasing interest in DNA-damaging drugs. Unlike the
era initiated with the discovery of the anticancer activity of
mechlorethamine in 1940s, it is more commonly accepted
thatthenewgoldeneraofcancerchemotherapyisdrivenbya
new series of drugs characterized by their capacity to interact
with targets expressed with high selectivity only by tumour
cells and this is now giving rise to drugs that are actually
available in clinical practice. It is clear that the “old drugs”
will still accompany us in the clinical treatment of tumours
for many years. It is similarly evident that the few improve-
ments we may expect from these drugs (those acting on nu-
cleic acids or on macromolecules of the mitotic spindle) are
those associated with a better pharmacokinetic proﬁle that
can lead to the reduction of systemic toxicity, the main prob-
lem limiting the use of such drugs.
Researchers are now convinced that targets such as DNA,
RNA, and tubulin do not provide suﬃcient selectivity for
cancer cells without negative eﬀects on healthy tissues. Also,
factors such as the high tendency to develop resistance
towards chemotherapeutic agents, the genetic instability of
tumour cells, their heterogeneity, and their elevated muta-
tion index are elements suﬃcient to circumvent the practi-
cal application of chemotherapy. Furthermore, we now have
new ways to develop and research ideas on the processes of
gene regulation involved in tumour malignancy: activation
and repression of signal transduction pathways depending
on various extracellular signals and/or cell mutations that se-
lecttheircapacitytosurvive,generatetumours,andtoinvade
and give rise to metastases, the ultimate target of chemother-
apy.
We therefore have important work to do: to obtain new
metal-based drugs that are not related to cisplatin or plat-
inum analogues currently in use or in the advanced stages of
development, since these represent part of the old strategy of
antitumour chemotherapy. We are conscious of the diﬃcul-
ties of the game but we will run this race with the important
advantage of having 40 years of accumulated experience with
a number of metals and ligands, signiﬁcant knowledge of the
chemical behavior of these compounds in solution and in
physiological media, and on their interactions with biolog-
ical molecules. The open-access journal Metal Based Drugs
represents an important aid to develop these topics and oth-
ers, for example, on diabetes and on molecular diagnostics
that we have not raised here but are equally important and
represent the opposite side of the same coin.
Good luck fellow colleagues
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